Immuneering
IMRX
50 hedge funds and large institutions have $88.1M invested in Immuneering in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 6 reducing their positions, and 1 closing their positions.
1,300% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 1
283% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 6
35% more funds holding
Funds holding: 37 → 50 (+13)
3.41% more ownership
Funds ownership: 48.19% → 51.6% (+3.4%)
56% less capital invested
Capital invested by funds: $200M → $88.1M (-$112M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.79M |
| 2 |
BlackRock
New York
|
+$3.91M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.62M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.27M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$17.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.58M |
| 3 |
Citigroup
New York
|
-$13.7K |
| 4 |
Millennium Management
New York
|
-$10.4K |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$9.4K |
IMRX Hedge Fund Activity: Q1 2022 in Review
50 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q1 2022, worth a combined $88.1M — down 56% from $200M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IMRX positions and 1 closed out — a net gain of 13 holders — while 23 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $4.79M. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $17.6M sold.
- 50 institutional investors held Immuneering (IMRX) as of Q1 2022, up from 37 in Q4 2021.
- Funds reported $88.1M of Immuneering stock for Q1 2022, down 56% quarter-over-quarter.
- 14 funds opened new Immuneering positions in Q1 2022 and 1 closed out, a net change of +13 holders.
- The largest Immuneering buyer in Q1 2022 was Vanguard Group, an estimated $4.79M added.
- The largest Immuneering seller in Q1 2022 was Rock Springs Capital Management, an estimated $17.6M sold.
Based on aggregated 13F filings for Q1 2022.